Daily Newsletter

29 August 2023

Daily Newsletter

29 August 2023

PureHealth to acquire UK’s Circle Health Group for $1.2bn

Circle Health Group operates 53 hospitals across the UK, serving a diverse patient base.

August 29 2023

Managed care company Centene has agreed to divest Circle Health Group, a British independent hospital operator, to UAE-based healthcare network PureHealth.

Valued at around $1.2bn, including debt, the transaction is part of US-based Centene's strategic focus on core business areas.

PureHealth CEO Farhan Malik said: “Our mission at PureHealth is to drive scientific innovation to unlock longevity and greater quality of life for humankind.

“Through integrating the expertise of both organisations, we positively impact the lives of patients globally. PureHealth, as the region's largest healthcare group, is well-positioned to make significant contributions to the improvement of healthcare systems and access to world-class medical services in the UAE and beyond."

The deal awaits regulatory clearance and is expected to be completed in Q1 2024.

Dickson Minto was the legal counsel to Centene for the transaction while Barclays was its financial adviser.

Centene CEO Sarah London said: “Circle Health is an innovative healthcare organisation that has had a significant impact for the benefit of patients across the UK.

“We are confident that this business will continue to thrive, providing access to high-quality care and delivering improved clinical outcomes under the ownership of Pure Health.

“This transaction marks another milestone in our portfolio review and showcases continued momentum against our value creation plan.”

Circle Health Group operates 53 hospitals across the UK, serving a diverse patient base.

The firm initially invested in Circle Health in 2019 and picked its remaining equity in 2021.

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close